A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients

International Clinical Psychopharmacology

Volumn 20, Issue 6, 2005, Pages 319-326

  Silver, Henry ^a,b   Goodman, Craig ^a   Isakov, Victoria ^a   Knoll, Gabriela ^a   Modai, Ilan ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Amantadine; Cognition; Cognitive enhancement; Dopamine; Schizophrenia

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; MENTAL HEALTH CENTER; NEUROPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; VISUOMOTOR COORDINATION;

ADULT; AMANTADINE; COGNITION; CROSS-OVER STUDIES; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA;

EID: 26944441259     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200511000-00007     Document Type: Article

References (65)

1. Andreasen NC (1983). Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: The University of Iowa.
2. Andreasen NC (1984). Scate for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: The University of Iowa.
3. 2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci 15:3429-3439.
4. Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK (2002). Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 159: 1490-1496.
5. Benton AL (1974). The Revised Visual Retention Test, 4th edn. New York, New York: Psychological Corporation.
6. Benton AL, Hannay HJ, Varney NR (1975). Visual perception of line direction in patients with unilateral brain disease. Neurology 25:907-910.
7. Bilder RM (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 42:255-264.
8. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 28:353-366.
9. Binns KE, Salt TE (1996). Importance of NMDA receptors for multimodal integration in the deep layers of the cat superior colliculus. J Neurophysiol 75:920-930.
10. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG (1990). Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16:477-499.
11. Coyle JT, Tsai G, Goff D (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003:318-327.
12. Delis DC, Kramer JH, Kaplan E, Ober BA (1987). California Verbal Learning Test: Adult Version Manual. San Antonio, Texas: The Psychological Corporation.
13. Erwin RJ, Gur RC, Gur RE, Skolnick B, Mawhinney-Hee M, Smailis J (1992). Facial emotion discrimination: I. Task construction and behavioral findings in normal subjects. Psychiatry Res 42:231-240.
14. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
15. Friedman JI, Temporini H, Davis KL (1999). Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45: 1-16.
16. Frith C (1995). Functional imaging and cognitive abnormalities. Lancet 346: 615-620.
17. Glahn DC, Gur RC, Ragland JD, Censits DM, Gur RE (1997). Reliability, performance characteristics, construct validity, and an initial clinical application of a visual object learning test (VOLT). Neuropsychology 11:602-612.
18. Glahn DC, Cannon TD, Gur RE, Ragland JD, Gur RC (2000). Working memory constrains abstraction in schizophrenia. Biol Psychiatry 47:34-42.
19. Goff DC, Wine L (1997). Glutamate in schizophrenia: clinical and research implications. Schizoph Res 27:157-168.
20. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE (1991). Cognitive and behavioral effects of the co-administration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148:78-84.
21. Goldman-Rakic PS, Selemon LD (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458.
22. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the 'Right Stuff? Schizophr Bull 26:119-136.
23. Gur RC, Jaggi JL, Ragland JD, Resnick SM, Shtasel D, Muenz L, Gur RE (1993). Effects of memory processing on regional brain activation: cerebral blood flow in normal subjects. Int J Neurosci 72:31-44.
24. Guy W (ed) (1976). National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Assessment Manual. Rockville, Maryland: US Department of Health and Human Services, pp. 534-537.
25. Hocherman S, Alexandrovsky L, Badarny S, Honigman S (1998). L-DOPA improves visuo-motor coordination in stable Parkinson's disease patients. Parkinson Relat Disord 4:129-136.
26. Hocherman S, Dimant A, Schwartz M (2003). Visuo-motor coordination is normal in patients with major depression. Parkinson Relat Disord 9:361-366.
27. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE (1992). Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 149:898-903.
28. Honey GD, Suckling J, Zelaya F, Long C, Routledge C, Jackson S, et al. (2003). Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain 126:1767-1781.
29. Jones P, Rodgers B, Murray R, Marmot M (1994). Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344: 1398-1402.
30. Kay SR, Opler LA, Lindenmayer JP (1987). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99-110.
31. Keefe RSE, Lees-Roitman SE, Dupre RL (1997). Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophr Res 26:9-14.
32. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999). The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review. and meta-analysis. Schizophr Bull 25:201-222.
33. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233.
34. Kurtz MM, Ragland JD, Bilker W, Gur RC, Gur RE (2001). Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia. Schizophr Res 48: 307-316.
35. Lange KW, Kornhuber J, Reiderer P (1997). Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21:393-400.
36. Liddle PF (1996). Functional imaging - schizophrenia. Br Med Bull 96:486-494.
37. Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy DL, Bogerts B, et al. (1993). Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. Arch Gen Psychiatry 50:357-368.
38. 2 dopamine receptor agonist. J Cogn Neurosci 4:58-68.
39. Medalla A, Gold J, Merriam A (1988). The effects of neuroleptics on neuropsychological test results in schizophrenia. Arch Clin Neurol 3: 249-271.
40. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
41. Purdon SE, Jones BDW, Stip E, Labelle A, Adington D, David SR, et al. (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249-258.
42. Reitan RM, Davison LA (1974). Clinical Neuropsychology: Current Status and Applications. New York, New York: Hemisphere.
43. Rosenberg DR, Sweeney JA, Squires-Wheeler E, Keshavan MS, Comblatt BA, Erlenmeyer-Kimling L (1997). Eye-tracking dysfunction in offspring from the New York High-Risk Project: diagnostic specificity and the role of attention. Psychiatry Res 66:121-130.
44. Ross DE, Thaker GK, Holcomb HH, Cascella NG, Medoff DR, Tamminga CA (1995). Abnormal smooth pursuit eye movements in schizophrenic patients are associated with cerebral glucose metabolism in oculomotor regions. Psychiatry Res 58:53-67.
45. Rubin P, Holm A, Moller-Madsen S, Videbech P, Hertel C, Povlsen UJ, Hemmingsen R (1995). Neuropsychological deficit in newly diagnosed patients with schizophrenia or schizophreniform disorder. Acta Psychiatr Scand 92:35-43.
46. Russell EW, Neuringer C, Goldstein G (1970). Assessment of Brain Damage. A Neuropsychological Key Approach. New York, New York: Wiley-Interscience.
47. Sakata H, Taira M, Kusunoki M, Murata A, Tanaka Y (1997). The TINS Lecture: The parietal association cortex in depth perception and visual control of hand action. TINS 20:350-357.
48. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. (1991). Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 48:141-162.
49. Schatz J (1998). Cognitive processing efficiency in schizophrenia: generalized versus domain specific deficits. Schizophr Res 30:41-49.
50. Schreiber H, Stolz-Born G, Heinrich H, Kornhuber HH, Born J (1992). Attention, cognition, and motor perseveration in adolescents at genetic risk for schizophrenia and control subjects. Psychiatry Res 44:125-140.
51. Schwartz AB (1994). Distributed motor processing in cerebral cortex. Curr Opin Neurobiol 4:840-846.
52. Schwartz M, Groshar D, Inzelberg R, Hocherman S (2004). Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. Parkinsonism Relat Disord 10:385-389.
53. Silver H, Feldman P (2005). Sustained attention and WM in schizophrenia may share a common mechanism. J Neuropsychiatry Clin Neurosci, in press.
54. Silver H, Geraisy N (1995). Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. A Double-blind cross-over study. Br J Psychiatry 166:241-243.
55. Silver H, Geraisy N (1996). Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol 16:463-464.
56. Silver H, Shlomo N, Schwartz M, Hocherman S (2002). Impaired visuomotor function in schizophrenic patients compared with control subjects. J Neuropsychiatry Clin Neurosci 14:72-76.
57. Silver H, Feldman P, Bilker W, Gur RC (2003). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 160: 1809-1816.
58. Silver H, Goodman C, Knoll G, Isakov V (2004). Brief emotion training improves recognition of facial emotions in chronic schizophrenia. A pilot study. Psychiatry Res 128:147-154.
59. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
60. Spohn HE, Strauss ME (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98: 367-380.
61. Tahar AH, Blanchet PJ, Doyon J (2004). Motor-learning impairment by amantadine in healthy volunteers. Neuropsychopharmacology 29:187-194.
62. Wechsler D (1998). Wechsler Adult Intelligence Scale Manual. New York, New York: Guilford Press, pp. 95-188.
63. Weiler MA, Thaker GK, Lahti AC, Tamminga CA (2000). Ketamine effects on eye movements. Neuropsychopharmacology 2000, 23:645-653.
64. Weinberger DR, Herman KF, Illowsky BP (1988). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 45:609-615.
65. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. 376:572-575.